Prestige BioPharma inks two new deals for its biosimilar trastuzumab
Category: #health  By Mateen Dalal  Date: 2019-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Prestige BioPharma inks two new deals for its biosimilar trastuzumab
  • The company would be able to supply and commercialize its biosimilar across Russia under the latest of the two deals.
     
  • The second deal, meanwhile, gives Prestige access to certain parts of Europe.

Prestige BioPharma (Prestige), a renowned Singapore-based biopharmaceutical company, has reportedly announced that it has signed two new agreements that would allow it to supply and commercialize its biosimilar trastuzumab, HD201, across Russia and parts of Europe.

Reports cite, the company signed the latest of the two deals with Pharmapark LLC, a private Russian pharmaceutical firm that is marketing five biosimilars across Russia at present. Meanwhile, the company inked the second deal with Mundipharma, a UK-based pharmaceutical company.

According to reports, the Mundipharma agreement would give the trastuzumab biosimilar access across a number of European countries including Spain, France, Sweden, Norway, Finland, Denmark, Austria, Switzerland and Portugal following the drug’s approval by the European Commission.

The CEO of Prestige BioPharma, Lisa S. Park, PhD, stated that the company is thrilled to collaborate with Mundipharma to commercialize its leading biosimilar across select European markets. Park further added that the proposed partnership is a crucial milestone for Prestige as it will boost the global availability of trastuzumab and benefit more patients through its accessibility and quality.

The new deals reportedly come as the latest in a string of agreements concerning the biosimilar for the Singapore-based biopharma company; in the fourth quarter of 2018, Prestige inked a licensing agreement with Cipla Limited to supply and commercialize trastuzumab across emerging markets. Earlier, the company also announced a deal with Alvogen to distribute the biosimilar across Eastern and Central Europe.

Sources familiar with the matter claim that the proposed biosimilar is currently being reviewed by the European Medicines Agency. Moreover, the company also plans to submit an application for the biosimilar with the U.S. FDA by the end of 2019.

Source Credits:

https://www.centerforbiosimilars.com/news/prestige-biopharma-strikes-2-more-deals-for-biosimilar-trastuzumab-hd201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...

Motorola Solutions buys WatchGuard to expand video security portfolio
Motorola Solutions buys WatchGuard to expand video security portfolio
By Mateen Dalal

WatchGuard’s solutions allow law enforcement users to manage high-quality video evidence Motorola Solutions, Inc., the US based data communications and telecommunications equipment provider, has recently announced the acquisition of WatchGuard...

Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
By Mateen Dalal

The study is formulated to evaluate the safety and efficacy of Oral KORSUVA for moderate to severe pruritus Biopharmaceutical firm Cara Therapeutics Inc. has reportedly announced the initiation of their Phase 2 trial of Oral KORSUVATM for pruritus t...